John Clement, PhD General Partner
Dr. Clement possesses over twenty years of experience in preclinical and clinical drug development, project and alliance management, and product acquisition. Dr. Clement co-founded iCo Therapeutics in 2005 and served as Chief Technology and Development Officer and Chief Business Officer during his tenure with the company. Prior to that he served as Director of Business Development and Director of Extramural Research at QLT Inc. and he has also served as Director of Extramural Research and Associate Director of Pharmacology and Toxicology at Biochem Pharma Inc., research scientist & manager with Department of National Defence (DND) and Research Scientist at CIBA-Geigy Canada Ltd. During his tenure with DND he held various scientific leadership / management positions and was responsible for the development of a new antidote for nerve agent poisoning (HI-6). He obtained a PhD (Pharmacology) from the University of Western Ontario and has published over 60 manuscripts.